You may earn this many credits: 1
Tobacco use is common among people with mental health disorders and most are not motivated to quit in the near future. Quitting smoking is often the single best thing a patient can do for their health but tobacco treatment is often a low priority for patients with co-occurring mental health disorders. In this presentation we will review the research on tobacco treatment and harm reduction for people with co-occurring mental health disorders who are unmotivated or feel unable to quit.
Please note: if you fail to successfully complete the learning assessment quiz at the end of this video after attempting to do so 3 times, you will have to re-purchase the video in order to re-take the quiz and earn your continuing education credit.
This workshop is designed to help clinicians:
1. Describe the impact that tobacco treatment can have for people who smoke and have a co-occurring mental health disorder.
2. Utilize an empirically supported brief motivational intervention to promote quitting among patients who are unmotivated or feel unable to quit tobacco.
3. Utilize an empirically supported brief reduction-based intervention to reduce harm and promote quitting among patients who are unmotivated or feel unable to quit tobacco.
The VPA Psychological Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The VPA Psychological Association maintains responsibility for this program and its content.
Slides used by presenter during live presentation.
|36 Pages||Available after Purchase|
Dr. Klemperer is a project director at the Vermont Center on Behavior and Health and an assistant professor at the UVM Larner College of Medicine in the psychiatry department.
His research focuses on substance use and co-occurring mental illness, medications for opioid use in justice settings; nicotine use and smoking cessation treatment; and other related topics. He was recently awarded a Justice Community Opioid Innovation Network Rapid Innovation Grant from NIH to study the implementation of medications for opioid use in the justice setting.
Dr. Klemperer received his Ph.D. at the University of Vermont and did post-doctoral training at Yale University and University of Vermont. He has published numerous papers and presented his research at numerous conferences.
Please wait ...